Display options
Cite
Findlay EG, Currie AJ, Zhang A, et al. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology. 2019;8(8):1608106doi: 10.1080/2162402X.2019.1608106.
Findlay, E. G., Currie, A. J., Zhang, A., Ovciarikova, J., Young, L., Stevens, H., McHugh, B. J., Canel, M., Gray, M., Milling, S. W. F., Campbell, J. D. M., Savill, J., Serrels, A., & Davidson, D. J. (2019). Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology, 8(8), 1608106. https://doi.org/10.1080/2162402X.2019.1608106
Findlay, Emily Gwyer, et al. "Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy." Oncoimmunology vol. 8,8 (2019): 1608106. doi: https://doi.org/10.1080/2162402X.2019.1608106
Findlay EG, Currie AJ, Zhang A, Ovciarikova J, Young L, Stevens H, McHugh BJ, Canel M, Gray M, Milling SWF, Campbell JDM, Savill J, Serrels A, Davidson DJ. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology. 2019 May 01;8(8):1608106. doi: 10.1080/2162402X.2019.1608106. eCollection 2019. PMID: 31413918; PMCID: PMC6682359.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2019 May 01;8(8):1608106. doi: 10.1080/2162402X.2019.1608106. eCollection 2019.

Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy.

Oncoimmunology

Emily Gwyer Findlay, Andrew J Currie, Ailiang Zhang, Jana Ovciarikova, Lisa Young, Holly Stevens, Brian J McHugh, Marta Canel, Mohini Gray, Simon W F Milling, John D M Campbell, John Savill, Alan Serrels, Donald J Davidson

Affiliations

  1. University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh, UK.
  2. School of Veterinary and Life Sciences, Murdoch University, Perth, Western Australia, Australia.
  3. Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
  4. Scottish National Blood Transfusion Service, Heriot Watt Research Park, Edinburgh, UK.

PMID: 31413918 PMCID: PMC6682359 DOI: 10.1080/2162402X.2019.1608106

Abstract

Immunization of patients with autologous,

Keywords: CD103; CD141; CD86; CLEC9A; Immunotherapy; PD1; cancer; cathelicidin; cross-presentation; dendritic cells; host defense peptide

References

  1. Blood. 2000 Nov 1;96(9):3029-39 - PubMed
  2. J Immunol. 2000 Dec 1;165(11):6037-46 - PubMed
  3. J Clin Oncol. 2000 Dec 1;18(23):3894-903 - PubMed
  4. Vaccine. 2002 Dec 19;20 Suppl 4:A8-A22 - PubMed
  5. Cancer Res. 2003 Jan 1;63(1):12-7 - PubMed
  6. J Immunol. 2004 Jan 15;172(2):1146-56 - PubMed
  7. J Immunol. 2004 Mar 15;172(6):3758-65 - PubMed
  8. Cancer Res. 2004 Sep 1;64(17):5934-7 - PubMed
  9. Curr Opin Immunol. 2005 Apr;17(2):170-4 - PubMed
  10. J Immunol. 2005 Jun 1;174(11):6592-7 - PubMed
  11. J Leukoc Biol. 2006 Sep;80(3):509-20 - PubMed
  12. Genome Biol. 2008 Jan 24;9(1):R17 - PubMed
  13. Science. 2008 Nov 14;322(5904):1097-100 - PubMed
  14. Immunity. 2009 Nov 20;31(5):823-33 - PubMed
  15. J Exp Med. 2009 Dec 21;206(13):3115-30 - PubMed
  16. Immunol Rev. 2010 Mar;234(1):177-98 - PubMed
  17. Immunol Rev. 2010 Mar;234(1):268-81 - PubMed
  18. J Exp Med. 2010 Apr 12;207(4):823-36 - PubMed
  19. J Exp Med. 2010 Jun 7;207(6):1247-60 - PubMed
  20. J Exp Med. 2010 Jun 7;207(6):1131-4 - PubMed
  21. N Engl J Med. 2010 Jul 29;363(5):411-22 - PubMed
  22. J Clin Oncol. 2011 Jan 20;29(3):330-6 - PubMed
  23. J Immunol. 2011 May 1;186(9):5184-92 - PubMed
  24. Int J Cancer. 2012 Jul 15;131(2):287-97 - PubMed
  25. J Exp Med. 2011 Sep 26;208(10):2005-16 - PubMed
  26. Blood. 2012 Jun 21;119(25):6052-62 - PubMed
  27. J Exp Med. 2012 May 7;209(5):935-45 - PubMed
  28. Immunity. 2012 Jul 27;37(1):60-73 - PubMed
  29. Front Immunol. 2012 Jul 18;3:214 - PubMed
  30. Cancer Res. 2013 Jan 1;73(1):128-38 - PubMed
  31. Oncoimmunology. 2013 Mar 1;2(3):e23431 - PubMed
  32. J Clin Invest. 2013 Aug;123(8):3383-94 - PubMed
  33. J Clin Invest. 2014 May;124(5):2246-59 - PubMed
  34. Blood. 2014 Nov 13;124(20):3081-91 - PubMed
  35. Front Immunol. 2014 Jul 28;5:326 - PubMed
  36. Cancer Cell. 2014 Nov 10;26(5):623-37 - PubMed
  37. Cancer Cell. 2014 Nov 10;26(5):638-52 - PubMed
  38. Nature. 2015 Mar 19;519(7543):300-1 - PubMed
  39. Immunity. 2015 Jun 16;42(6):1197-211 - PubMed
  40. Oncoimmunology. 2015 Apr 2;4(8):e1019198 - PubMed
  41. Cell. 2015 Sep 24;163(1):160-73 - PubMed
  42. Clin Cancer Res. 2016 May 1;22(9):2155-66 - PubMed
  43. Oncoimmunology. 2015 Oct 29;5(1):e1104448 - PubMed
  44. Immunity. 2016 Apr 19;44(4):924-38 - PubMed
  45. Methods Mol Biol. 2016;1423:19-37 - PubMed
  46. Cancer Cell. 2016 Aug 8;30(2):324-336 - PubMed
  47. Cell Res. 2017 Jan;27(1):74-95 - PubMed
  48. Cell Rep. 2018 Aug 14;24(7):1902-1915.e6 - PubMed
  49. Nat Biomed Eng. 2018 Jun;2(6):341-346 - PubMed
  50. J Clin Invest. 1994 Apr;93(4):1846-51 - PubMed

Publication Types

Grant support